SCOPE 2-Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography

被引：13
作者：
Bridges, S. [1 ]
Thomas, B. [2 ]
Radhakrishna, G. [3 ]
Hawkins, M. [4 ]
Holborow, A. [5 ]
Hurt, C. [1 ]
Mukherjee, S. [6 ]
Nixon, L. [1 ]
Crosby, T. [2 ]
Gwynne, S. [5 ,7 ]
机构：
[1] Cardiff Univ, Ctr Trials Res, Cardiff, Wales
[2] Velindre Univ NHS Trust, Cardiff, Wales
[3] Christie NHS Fdn Trust, Manchester, Lancs, England
[4] UCL, Med Phys & Biomed Engn, London, England
[5] South West Wales Canc Ctr, Swansea, W Glam, Wales
[6] Univ Oxford, Oxford Inst Radiat Oncol, Oxford, England
[7] Swansea Univ, Med Sch, Swansea, W Glam, Wales
来源：
CLINICAL ONCOLOGY | 2022年 / 34卷 / 07期
关键词：
Dose escalation; radiotherapy; systemic therapy personalisation; oesophageal; PROTON-BEAM THERAPY; SIMULTANEOUS INTEGRATED BOOST; PREOPERATIVE CHEMORADIOTHERAPY; ESOPHAGOGASTRIC JUNCTION; METABOLIC-RESPONSE; CHEMOTHERAPY; RADIATION; CARCINOMA; PATTERNS; CARBOPLATIN/PACLITAXEL;
D O I：
10.1016/j.clon.2022.03.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The SCOPE 2 trial of definitive chemoradiotherapy in oesophageal cancer investigates the benefits of radiotherapy dose escalation and systemic therapy optimisation. The trial opened in 2016. The landscape of oesophageal cancer treatment over the lifetime of this trial has changed significantly and the protocol has evolved to reflect this. However, with the recent results of the Dutch phase III ART DECO study showing no improvement in local control or overall survival with radiotherapy dose escalation in a similar patient group, we sought to determine if the SCOPE 2 trial is still answering the key unanswered questions for oesophageal radiotherapy. Here we discuss the rationale behind the SCOPE 2 trial, outline the trial schema and review current data on dose escalation and outline recommendations for future areas of research. (C) 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：E269 / E280
页数：12
相关论文
共 58 条
  • [1] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, Yung-Jue
    Van Cutsem, Eric
    Feyereislova, Andrea
    Chung, Hyun C.
    Shen, Lin
    Sawaki, Akira
    Lordick, Florian
    Ohtsu, Atsushi
    Omuro, Yasushi
    Satoh, Taroh
    Aprile, Giuseppe
    Kulikov, Evgeny
    Hill, Julie
    Lehle, Michaela
    Ruschoff, Josef
    Kang, Yoon-Koo
    [J]. LANCET, 2010, 376 (9742) : 687 - 697
  • [2] Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy
    Boggs D.H.
    Hanna A.
    Burrows W.
    Horiba N.
    Suntharalingam M.
    [J]. Journal of Gastrointestinal Cancer, 2015, 46 (2) : 131 - 137
  • [3] Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial
    Bourhis, Jean
    Sire, Christian
    Graff, Pierre
    Gregoire, Vincent
    Maingon, Philippe
    Calais, Gilles
    Gery, Bernard
    Martin, Laurent
    Alfonsi, Marc
    Desprez, Patrick
    Pignon, Thierry
    Bardet, Etienne
    Rives, Michel
    Geoffrois, Lionel
    Daly-Schveitzer, Nicolas
    Sen, Sok
    Tuchais, Claude
    Dupuis, Olivier
    Guerif, Stephane
    Lapeyre, Michel
    Favrel, Veronique
    Hamoir, Marc
    Lusinchi, Antoine
    Temam, Stephane
    Pinna, Antonella
    Tao, Yun Gan
    Blanchard, Pierre
    Auperin, Anne
    [J]. LANCET ONCOLOGY, 2012, 13 (02) : 145 - 153
  • [4] Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer
    Boustani, Jihane
    Del Campo, Eleonor Rivin
    Blanc, Julie
    Peiffert, Didier
    Benezery, Karine
    Pereira, Renata
    Rio, Emmanuel
    Le Prise, Elisabeth
    Crehange, Gilles
    Huguet, Florence
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (02): : 329 - 337
  • [5] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
    Bradley, Jeffrey D.
    Paulus, Rebecca
    Komaki, Ritsuko
    Masters, Gregory
    Blumenschein, George
    Schild, Steven
    Bogart, Jeffrey
    Hu, Chen
    Forster, Kenneth
    Magliocco, Anthony
    Kavadi, Vivek
    Garces, Yolanda I.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Cliff
    Wynn, Raymond B.
    Koprowski, Christopher
    Meng, Joanne
    Beitler, Jonathan
    Gaur, Rakesh
    Curran, Walter, Jr.
    Choy, Hak
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 187 - 199
  • [6] STUDY TO DETERMINE ADEQUATE MARGINS IN RADIOTHERAPY PLANNING FOR ESOPHAGEAL CARCINOMA BY DETAILING PATTERNS OF RECURRENCE AFTER DEFINITIVE CHEMORADIOTHERAPY
    Button, Michael R.
    Morgan, Carys A.
    Croydon, Elizabeth S.
    Roberts, S. Ashley
    Crosby, Thomas D. L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03): : 818 - 823
  • [7] Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer
    Chen, Dawei
    Menon, Hari
    Verma, Vivek
    Seyedin, Steven N.
    Ajani, Jaffer A.
    Hofstetter, Wayne L.
    Quynh-Nhu Nguyen
    Chang, Joe Y.
    Gomez, Daniel R.
    Amini, Arya
    Swisher, Stephen G.
    Blum, Mariela A.
    Younes, Ahmed, I
    Barsoumian, Hampartsoum B.
    Erasmus, Jeremy J.
    Lee, Jeffrey H.
    Bhutani, Manoop S.
    Hess, Kenneth R.
    Minsky, Bruce D.
    Welsh, James W.
    [J]. JAMA ONCOLOGY, 2019, 5 (11) : 1597 - 1604
  • [8] Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial
    Chen, Yun
    Ye, Jinjun
    Zhu, Zhengfei
    Zhao, Weixin
    Zhou, Jialiang
    Wu, Chaoyang
    Tang, Huarong
    Fan, Min
    Li, Ling
    Lin, Qin
    Xia, Yi
    Li, Yunhai
    Li, Jiancheng
    Jia, Huixun
    Lu, Saiquan
    Zhang, Zhen
    Zhao, Kuaile
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (20) : 1695 - +
  • [9] Crehange G, 2021, INT J RADIAT ONCOL, V111, pS5, DOI 10.1016/j.ijrobp.2021.07.045
  • [10] Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy plus /- cetuximab in oesophageal cancer
    Crosby, T.
    Hurt, C. N.
    Falk, S.
    Gollins, S.
    Staffurth, J.
    Ray, R.
    Bridgewater, J. A.
    Geh, J. I.
    Cunningham, D.
    Blazeby, J.
    Roy, R.
    Maughan, T.
    Griffiths, G.
    Mukherjee, S.
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (06) : 709 - 716
123456